newsfilter
← Earnings
Earnings Releases·

Pelthos Therapeutics — Third Quarter 2026 Earnings Summary

  • Net product revenue for Zelsuvmi® rose 114% year-over-year to $15.2 million, while total revenue reached $15.4 million; net loss narrowed significantly to $(7.9) million from $(16.2) million a year ago and $(23.4) million in Q2 2026.
  • Management targets the Q1 2027 launch of Xepi® and Q3 2027 launch of Xeglyze®, with the transformative merger with Castle Creek expected to close by end of Q1 2027, creating a diversified portfolio including the late-stage asset D-Fi.
  • The company secured an additional $10.0 million from its Horizon Technology Finance facility in October 2026, bringing total borrowings to $40.0 million, while cash balance stood at $17.7 million as of September 30, 2026.
  • Zelsuvmi® formulary coverage expanded to 127 million commercially covered lives and over 70 million Medicaid lives, with unit volume increasing 365% year-over-year to 12,384 units dispensed.
Company
PELTHOS THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology